Over the past year, Exploration of Targeted Anti-tumor Therapy has achieved an increasing impact and larger number of citations. We sincerely thank everyone's great support! At the beginning of 2024, we are thrilled to announce and recognize the winners of "Highly Cited Paper Award 2023" to show our appreciation to those authors.

Criteria for selection and award:

● All articles published in 2022-2023;

● Both regular and special issue submissions are considered;

● Citations are counted according to Web of Science (WOS) in 2023;

● Prize for the author team: 300-1,000 USD, certificate of "Highly Cited Paper Award";

● Prize for the corresponding Guest Editor(s): 100-300 USD.

Winning Papers:

★ New antibody-drug conjugates (ADCs) in breast cancer—an overview of ADCs recently approved and in later stages of development

 Kira-Lee Koster, Jens Huober, Markus Joerger*

 Special Issue: Antibody-Drug Conjugates

★Potential role of resveratrol and its nano-formulation as anti-cancer agent

 Akshay Kumar, Balak Das Kurmi, Amrinder Singh, Dilpreet Singh*

 Special Issue: Plant Extracts as an Infinite Resource for New Anticancer Agents

★Genomic alterations in cholangiocarcinoma: clinical significance and relevance to therapy

 Marianeve Carotenuto, Alessandra Sacco, Laura Forgione, Nicola Normanno*

 Special Issue: Precision Medicine for Cholangiocarcinoma

Congratulations! We believe these articles will be more shining in the future.

In the following year, we will continue to set "Highly Cited Paper Award" to recognize the related authors. On behalf of the Editorial Board and Editorial Office, we warmly welcome more outstanding researchers to participate in and contribute to the journal. Our thriving journal is always open to you!